Meredith Goldwasser - Prime Medicine, Senior Operations

All Insiders . USA . 
Etf . Prime Medicine, Common . Stakeholders . Insider . Meredith Goldwasser
PRME Etf  USD 3.30  0.04  1.20%   
Meredith Goldwasser is Portfolio Manager at Prime Medicine, Common
Age 53
Address 21 Erie Street, Cambridge, MA, United States, 02139
Phone617 564 0013
Webhttps://primemedicine.com

Meredith Goldwasser Latest Insider Activity

Tracking and analyzing the buying and selling activities of Meredith Goldwasser against Prime Medicine, etf is an integral part of due diligence when investing in Prime Medicine,. Meredith Goldwasser insider activity provides valuable insight into whether Prime Medicine, is net buyers or sellers over its current business cycle. Note, Prime Medicine, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Prime Medicine,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Meredith Goldwasser over a month ago
Acquisition by Meredith Goldwasser of 90498 shares of Prime Medicine, at 8.49 subject to Rule 16b-3

Prime Medicine, Management Efficiency

The company has return on total asset (ROA) of (0.4651) % which means that it has lost $0.4651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1435) %, meaning that it created substantial loss on money invested by shareholders. Prime Medicine,'s management efficiency ratios could be used to measure how well Prime Medicine, manages its routine affairs as well as how well it operates its assets and liabilities.
Prime Medicine, Common currently holds 13.63 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Prime Medicine, Common has a current ratio of 6.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prime Medicine, until it has trouble settling it off, either with new capital or with free cash flow. So, Prime Medicine,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prime Medicine, Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prime to invest in growth at high rates of return. When we think about Prime Medicine,'s use of debt, we should always consider it together with cash and equity.

Similar Fund Executives

Showing other executives

One Year Return

Jim WattersRelay Therapeutics
N/A
Robert SweeneyOcean Biomedical
59
Michael CPABlueprint Medicines Corp
52
Christina MBABlueprint Medicines Corp
48
Douglas CPACentury Therapeutics
N/A
Richard MulliganSana Biotechnology
69
Sonja MDSana Biotechnology
49
Alessandra SassunRoyalty Pharma Plc
N/A
Raju PrasadCrispr Therapeutics AG
40
MD MBAOcean Biomedical
59
Karen TepichinGinkgo Bioworks Holdings
N/A
Esq CPAOcean Biomedical
59
Daniel PoonCaribou Biosciences
N/A
Sara KlymkowskyRoyalty Pharma Plc
N/A
Ariel HurleyBlueprint Medicines Corp
50
Yuko JDSana Biotechnology
N/A
Samarth KulkarniCrispr Therapeutics AG
46
Deborah PalestrantRelay Therapeutics
N/A
Timothy MBACaribou Biosciences
55
Amy CFACaribou Biosciences
N/A
Brian JDRelay Therapeutics
50
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. Prime Medicine, Common [PRME] is traded in USA and was established 2015-11-11. Prime Medicine, is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-1.14
Return On Asset-0.47

Prime Medicine, Common Money Managers

David Liu, CoFounder Board
Meredith Goldwasser, Senior Operations
Andrew MD, CoFounder Platform
Richard Brudnick, Chief Officer
Keith MD, CEO and President
Ann Lee, Chief Officer
Karen JD, Senior Affairs
Allan MD, Chief Officer
Niamh Alix, Chief Officer
Keith Gottesdiener, CEO and Presidentident

Prime Etf Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Prime Medicine, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.14
Return On Asset-0.47
Operating Margin(259.48) %
Current Valuation298.55 M
Shares Outstanding131.16 M
Shares Owned By Insiders23.90 %
Shares Owned By Institutions62.31 %
Number Of Shares Shorted15.19 M
Price To Earning14.40 X
Price To Book2.28 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Other Information on Investing in Prime Etf

Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY